MEDP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ME

Mkt Cap

$17.26B

Volume

248.76K

Next Earnings

October 21st

Loading chart

ME

MEDPMedpace Holdings, Inc. Common Stock

MEDP

Pay with—

Available Balance0.00

ME

Mkt Cap

$17.55B

Volume

248.76K

Next Earnings

October 21st

Chart Financials Earnings News About Insider Filings

CON vs. MEDP: Which Stock Should Value Investors Buy Now?In a comparison of two Medical Services stocks, Concentra Group (CON) emerges as the superior value option compared to Medpace (MEDP). CON holds a Zacks Rank of #2 (Buy) with improving earnings outlook and more attractive valuation metrics, including a forward P/E of 22.74 versus MEDP's 34.77, and a PEG ratio of 1.37 versus 2.72. CON also received a Value grade of B compared to MEDP's D grade.Zacks Investment Research · Oct 14, 2026

Medpace (MEDP) Dips More Than Broader Market: What You Should KnowMedpace (MEDP) closed down 1.64% and currently holds a Zacks Rank #3 (Hold) rating. The stock trades at a Forward P/E of 35.35, significantly above the industry average of 17.86, and a PEG ratio of 2.77 versus the industry average of 1.67. While earnings are expected to grow 15.28% next quarter and 14.79% for the full year, the premium valuation suggests limited upside potential in the near term.Zacks Investment Research · Oct 13, 2026

Medpace (MEDP) Stock Declines While Market Improves: Some Information for InvestorsMedpace stock declined 2.84% on October 6, 2026, underperforming the broader market gains. The company is expected to report earnings on October 21 with projected EPS of $4.45 (up 15.28% YoY) and revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a premium valuation with a Forward P/E of 35.38 versus the industry average of 16.59, and holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Oct 6, 2026

Medpace (MEDP) Rises As Market Takes a Dip: Key FactsMedpace (MEDP) closed at $622.11, up 1% and outperforming the S&P 500. The clinical development services provider is expected to report Q3 2026 earnings of $4.45 per share (up 15.28% YoY) with revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a Forward P/E of 35.12, significantly above the industry average of 16.95, and carries a Zacks Rank #3 (Hold) rating with no recent estimate revisions.Zacks Investment Research · Sep 29, 2026

Medpace (MEDP) Outperforms Broader Market: What You Need to KnowMedpace (MEDP) closed at $624.20, up 1.94%, outperforming the S&P 500's 1.49% gain. The clinical development services provider has a Zacks Rank #3 (Hold) rating with projected EPS growth of 15.28% and revenue growth of 7.4% for the upcoming quarter. However, the stock trades at a Forward P/E of 34.91, significantly above the industry average of 17.31, and has a PEG ratio of 2.73 compared to the industry average of 1.48, suggesting premium valuation.Zacks Investment Research · Sep 21, 2026

CON vs. MEDP: Which Stock Is the Better Value Option?A comparison of two Medical Services sector stocks reveals that Concentra Group (CON) is more attractive to value investors than Medpace (MEDP). CON has a stronger Zacks Rank (#1 vs #2), lower valuation multiples (forward P/E of 20.95 vs 33.25, PEG ratio of 1.26 vs 2.60, and P/B ratio of 9.04 vs 37.52), and a better Value grade (B vs D), making it the superior option for value-focused investors.Zacks Investment Research · Sep 11, 2026

Safirstein Law LLC Announces That A Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP)A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April 22, 2025 through February 9, 2026.GlobeNewswire Inc. · Jun 8, 2026

MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDPRosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are mentioned for Veritone, Inc. and Babcock & Wilcox Enterprises, Inc.GlobeNewswire Inc. · Jun 7, 2026

Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.GlobeNewswire Inc. · Jun 5, 2026

ROSEN, A LEADING LAW FIRM, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERIRosen Law Firm is urging investors who purchased Veritone, Inc. securities between October 14, 2025 and April 14, 2026 to join a class action lawsuit before the July 20, 2026 lead plaintiff deadline. The lawsuit alleges that Veritone made false statements about its financial performance, inaccurately recorded revenue and costs, overstated assets, and maintained deficient internal controls, leading to required financial statement restatements.GlobeNewswire Inc. · Jun 5, 2026

to start trading

ME

MEDPMedpace Holdings, Inc. Common Stock

MEDP

Pay with—

Available Balance0.00

Your PositionYou don't own any MEDP yet.

Related Tickers

Earnings